Avadel Pharmaceuticals PLC
NASDAQ: AVDL · HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC
Updated 2026-02-12
Avadel Pharmaceuticals PLC (AVDL) Financial statements
SEC filings — annual and quarterly data.
Cash flow — annual
| Item | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $-19.39M | $-29.83M | $-19.24M | $-7.51M | $8.20M | $-5.46M | $-10.32M | $-23.14M | $-20.68M | $-10.62M | $84.29M | $18.90M | $16.66M | $-82.72M | $-38.33M | $-48.73M | $-77.31M | $-70.30M | $-128.51M | $-46.91M |
| Capital expenditures | $11.33M | $6.39M | $11.27M | $3.52M | $1.77M | $3.60M | $1.90M | $1.07M | $1.03M | $1.73M | $1.63M | $1.20M | $53.70M | $20.18M | $29000.00 | $98000.00 | $26000.00 | $716000.00 | $0.00 | $0.00 |
| Depreciation | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Stock-based comp | $1.39M | $546000.00 | $9.99M | $8.29M | $5.50M | $3.17M | $2.78M | $3.04M | $2.03M | $2.69M | $7.74M | $14.68M | $8.07M | $7.85M | $519000.00 | $3.00M | $8.87M | $7.01M | $15.81M | $20.39M |
| Free cash flow | $-30.71M | $-36.22M | $-30.51M | $-11.03M | $6.42M | $-9.06M | $-12.23M | $-24.21M | $-21.70M | $-12.35M | $82.66M | $17.70M | $-37.04M | $-102.89M | $-38.35M | $-48.83M | $-77.34M | $-71.02M | $-128.51M | $-46.91M |
| Investing cash flow | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Financing cash flow | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Dividends paid | — | — | — | — | — | — | — | — | — | — | $0.00 | $0.00 | $0.00 | — | — | — | — | — | — | — |
| Share repurchases | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Debt repayment | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Net change in cash | — | — | — | — | — | — | — | — | — | — | $25.30M | $-25.85M | $-22.65M | $-7.24M | $371000.00 | $61.23M | $-20.12M | — | — | — |
Frequently asked questions
What is Avadel Pharmaceuticals PLC's revenue?
Avadel Pharmaceuticals PLC's trailing twelve-month revenue is $248.52M. Revenue is the top line the whole model builds on, and at this scale the question shifts from how fast it grows to whether margins hold as it compounds.
How profitable is AVDL?
In its most recent fiscal year, AVDL ran a gross margin of 90.97%, an operating margin of -25.07%, and a net margin of -28.87%. Margins this high mean most of each extra dollar of revenue drops through to profit, which is the signature of real pricing power.
How much free cash flow does AVDL generate?
AVDL produced $-46.91M in free cash flow in its most recent fiscal year. Free cash flow is what is left after running and reinvesting in the business, and it is the cash that actually funds buybacks, dividends, and a stronger balance sheet.
Is AVDL's balance sheet healthy?
AVDL holds $51.37M in cash and equivalents against — in long-term debt, on $73.85M of shareholder equity. That debt is best read against the cash flow the business throws off each year.